{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:19:35Z","timestamp":1791425975454,"version":"4.3.3"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Interferon (IFN) is an innate immune response protein that is involved in the antiviral response during viral infection. Treatment of acute viral infections with exogenous interferon may be effective but is generally not feasible for clinical use due to many factors, including cost, stability, and availability. To overcome these limitations, an adenovirus type 5-vectored consensus alpha IFN, termed DEF201, was constructed as a potential way to deliver sustained therapeutic levels of systemic IFN. To demonstrate the efficacy of DEF201 against acute flaviviral disease, various concentrations of the construct were administered as a single intranasal dose prior to virus infection, which resulted in a dose-responsive, protective effect in a hamster model of yellow fever virus (YFV) disease. A DEF201 dose of 5 \u00d7 10\n            <jats:sup>7<\/jats:sup>\n            PFU\/animal administered intranasally just prior to YFV challenge protected 100% of the animals, while a 10-fold lower DEF201 dose exhibited lower, although significant, levels of protection. Virus titers in the liver and serum and levels of serum alanine aminotransferase were all significantly reduced as a result of DEF201 administration at all doses tested. No toxicity, as indicated by weight loss or gross morbidity, was observed in non-YFV-infected animals treated with DEF201. Protection of YFV-infected animals was observed when DEF201 was delivered as early as 7 days prior to virus challenge and as late as 2 days after virus challenge, demonstrating effective prophylaxis and therapy in a hamster model of disease. Overall, it appears that DEF201 is effective in the treatment of YFV in a hamster model.\n          <\/jats:p>","DOI":"10.1128\/aac.01635-10","type":"journal-article","created":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T05:34:48Z","timestamp":1297143288000},"page":"2067-2073","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":42,"title":["Treatment of Yellow Fever Virus with an Adenovirus-Vectored Interferon, DEF201, in a Hamster Model"],"prefix":"10.1128","volume":"55","author":[{"given":"Justin G.","family":"Julander","sequence":"first","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, Logan, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Ennis","sequence":"additional","affiliation":[{"name":"Defyrus Inc., 2 Bloor Street W, Suite 2602, Toronto, Ontario M4W 3E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Turner","sequence":"additional","affiliation":[{"name":"Defyrus Inc., 2 Bloor Street W, Suite 2602, Toronto, Ontario M4W 3E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Morrey","sequence":"additional","affiliation":[{"name":"Institute for Antiviral Research, Utah State University, Logan, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4508-4514.2005"},{"key":"e_1_3_2_3_2","first-page":"413","article-title":"Development of antibodies to interferon beta in patients: technical and biological aspects","volume":"10","author":"Antonelli G.","year":"1999","unstructured":"AntonelliG. DianzaniF.. 1999. Development of antibodies to interferon beta in patients: technical and biological aspects. Eur. Cytokine Netw. 10:413\u2013422.","journal-title":"Eur. Cytokine Netw"},{"key":"e_1_3_2_4_2","first-page":"647","article-title":"Effect of human gamma interferon on yellow fever virus infection","volume":"38","author":"Arroyo J. I.","year":"1988","unstructured":"ArroyoJ. I. . 1988. Effect of human gamma interferon on yellow fever virus infection. Am. J. Trop. Med. Hyg. 38:647\u2013650.","journal-title":"Am. J. Trop. Med. Hyg"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.12.001"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(98)00063-1"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.7.2293-2298.2003"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(02)00185-7"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003548"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.02.009"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01316787"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.630"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.30.1.52"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-3542(85)80028-0"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.1998.0050s1013.x"},{"key":"e_1_3_2_16_2","first-page":"1354","article-title":"Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects","volume":"9","author":"Hutson T. E.","year":"2003","unstructured":"HutsonT. E. . 2003. Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects. Clin. Cancer Res. 9:1354\u20131360.","journal-title":"Clin. Cancer Res"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.08.015"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01494-06"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.08.008"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2010.11.007"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01161-09"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.3.455"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.2.777-782.2003"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/605847"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.10.009"},{"key":"e_1_3_2_26_2","first-page":"341","article-title":"Yellow fever as an endemic\/epidemic disease and priorities for vaccination","volume":"99","author":"Monath T. P.","year":"2006","unstructured":"MonathT. P. 2006. Yellow fever as an endemic\/epidemic disease and priorities for vaccination. Bull. Soc Pathol. Exot. 99:341\u2013347.","journal-title":"Bull. Soc Pathol. Exot"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/095632020401500202"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2004.02.005"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.13.8004-8013.2005"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.006833-0"},{"key":"e_1_3_2_31_2","first-page":"493","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed L. J.","year":"1938","unstructured":"ReedL. J. MuenchC. H.. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493\u2013497.","journal-title":"Am. J. Hyg"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61593-7"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12709-2"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/10408360490497474"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2006.04.001"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1086\/651018"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60469-4"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2007.07.024"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01635-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01635-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:28:00Z","timestamp":1645486080000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01635-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["10.1128\/AAC.01635-10"],"URL":"https:\/\/doi.org\/10.1128\/aac.01635-10","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"2010-11-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-01-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-04-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}